Year: 2024

leopharma

LEO Pharma Announces Topline Results of Phase 3 Trial in China for Enstilar® (LEO 90100) Demonstrating Superiority in Adult Chinese Subjects With Stable Plaque Psoriasis

Enstilar® (LEO 90100) showed superiority over Daivobet® ointment in primary and both secondary endpoints in the testing hierarchy showing improved...